Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study |
| |
| Institution: | 1. National Center of Hematology and University College of Medicine, Baghdad, Iraq;2. University Hospital CHU Mustapha, Algiers, Algeria;3. Hammoud Hospital, Sidon, Lebanon;4. Cairo University, Cairo, Egypt;5. Iraqi CML Patient Organization, Iraq;6. Hematology Research Center, Nemazee Hospital, Shiraz, Iran;7. King Saud Medical City, Riyadh, Saudi Arabia;8. Al-Kindy College of Medicine, Baghdad University, Baghdad, Iraq;9. Madinah Blood Disorders Center, King Abdullah Medical City, Madinah, Saudi Arabia;10. Pediatric Oncology & Hematology Center, Casablanca, Morocco;11. Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK;12. International Network of Hematology, London, UK;13. Iranian Thalassemia Society, Iran;1. Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, South Korea;2. Department of Laboratory Medicine, Medical Research Institute, Busan National University Hospital, Busan, South Korea;3. Sinai Center for Thrombosis Research, Baltimore, MA, United States |
| |
| Abstract: | BackgroundAlthough no data have been reported beyond second-line therapy, aflibercept is approved in this setting in many countries. We conducted a multicenter study to analyze the efficacy and safety of a aflibercept–chemotherapy regimen beyond second-line therapy in patients with metastatic colorectal cancer.Patients and MethodsMetastatic colorectal cancer patients treated with aflibercept beyond second-line therapy were included. Objective response rate, overall survival (OS), and progression-free survival (PFS) were assessed.ResultsA total of 130 patients were included. Median OS and PFS were 7.6 months (95% confidence interval, 6.2-9.3) and 3.3 months (95% confidence interval, 2.7-3.8), respectively. The best response rates were partial response 6.9%, stable disease 38.5%, progressive disease 42.5%, and not evaluable 12%. According to whether patients received previous FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin)-bevacizumab or not, OS was 7.7 and 8.1 months (P = .31), and PFS was 2.9 and 3.9 months (P = .02), respectively. Interestingly, PFS and OS were both significantly improved by 4% and 5% per month, respectively, without antiangiogenic treatment before the initiation of the aflibercept regimen. The negative effect of prior FOLFIRI–bevacizumab or shorter time since last bevacizumab was maintained in multivariate analysis for both OS and PFS.ConclusionThe aflibercept–chemotherapy regimen is a therapeutic option in patients with chemorefractory disease beyond second-line therapy, in particular in patients with an antiangiogenic-free interval. |
| |
| Keywords: | Acquired resistance Advanced disease Antiangiogenic Metastatic colorectal cancer Outcomes |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
